Postoperative moderately hypofractionated radiotherapy in prostate cancer: a mono-institutional propensity-score-matching analysis between adjuvant and early-salvage radiotherapy

[1] Thompson IM(2009)Adjuvant radiotherapy for pathologic T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial J Urol 181 956-962

[2] Tangen CM(2012)Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) Lancet 380 2018-27

[3] Paradelo J(2014)Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96–02/AUO AP 09/95 trial Eur Urol 66 243-250

[4] Bolla M(2016)A cast of shadow on adjuvant radiotherapy for prostate cancer: A critical review based on a methodological perspective Crit Rev Oncol Hematol 97 322-7

[5] van Poppel H(2014)Do screening trial recruitment logs accurately reflect the eligibility criteria of a given clinical trial? Early lessons from the RAVES 0803 trial Clin Oncol (R Coll Radiol) 26 348-352

[6] Tombal B(2012)Current controversies in the management of biochemical failure in prostate cancer Clin Adv Hematol Oncol 10 716-722

[7] Vekemans K(2020)Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 0803/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial Lancet Oncol 21 1331-1340

[8] Da Pozzo L(2020)Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial Lancet 396 1413-1421

[9] de Reijke TM(2020)Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial Lancet Oncol 21 1341-1352

[10] Verbaeys A(2018)Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series Radiol Med 123 719-725

[1] Thompson IM(2009)Adjuvant radiotherapy for pathologic T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial J Urol 181 956-962

[2] Tangen CM(2012)Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) Lancet 380 2018-27

[3] Paradelo J(2014)Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96–02/AUO AP 09/95 trial Eur Urol 66 243-250

[4] Bolla M(2016)A cast of shadow on adjuvant radiotherapy for prostate cancer: A critical review based on a methodological perspective Crit Rev Oncol Hematol 97 322-7

[5] van Poppel H(2014)Do screening trial recruitment logs accurately reflect the eligibility criteria of a given clinical trial? Early lessons from the RAVES 0803 trial Clin Oncol (R Coll Radiol) 26 348-352

[6] Tombal B(2012)Current controversies in the management of biochemical failure in prostate cancer Clin Adv Hematol Oncol 10 716-722

[7] Vekemans K(2020)Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 0803/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial Lancet Oncol 21 1331-1340

[8] Da Pozzo L(2020)Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial Lancet 396 1413-1421

[9] de Reijke TM(2020)Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial Lancet Oncol 21 1341-1352

[10] Verbaeys A(2018)Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series Radiol Med 123 719-725